Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company’s novel oral antifungal compound, in patients with moderate-to-severe interdigital tinea pedis , also known as athlete’s foot.
March 12, 2014 - Business Wire via Yahoo! Finance